US Researchers Develop New mRNA Vaccine To Fight Covid-19
New Delhi:
Amid fresh surge in Covid-19 cases, a team of US researchers has developed a new type of mRNA vaccine that is more scalable and adaptable to tackle continuously evolving viruses such as SARS-CoV-2 and H5N1.
While the currently available mRNA vaccines are highly effective at inducing an immune response against Covid, they present challenges like the high amount of mRNA needed to produce them and the constantly evolving nature of the pathogen.
"The virus changes, moving the goal post, and updating the vaccine takes some time," said senior author Suresh Kuchipudi, chair of Infectious Diseases and Microbiology at the University of Pittsburgh School of Public Health.
To address these challenges, the researchers created a proof-of-concept Covid vaccine using what's known as a "trans-amplifying" mRNA platform.
In this approach, the mRNA is separated into two fragments -- the antigen sequence and the replicase sequence -- the latter of which can be produced in advance, saving crucial time in the event a new vaccine must be developed urgently and produced at scale.
In addition, the researchers analysed the spike-protein sequences of all known variants of the SARS-CoV-2 for commonalities, rendering what's known as a "consensus spike protein" as the basis for the vaccine's antigen.
In mice, the vaccine induced a robust immune response against many strains of SARS-CoV-2.
"This has the potential for more lasting immunity that would not require updating, because the vaccine has the potential to provide broad protection," said Kuchipudi.
"Additionally, this format requires an mRNA dose 40 times less than conventional vaccines, so this new approach significantly reduces the overall cost of the vaccine."
The study, published in the journal npj Vaccines could inform more efficient vaccine development for other constantly evolving RNA viruses with pandemic potential, Kuchipudi said.
"We hope to apply the principles of this lower-cost, broad-protection antigen design to pressing challenges like bird flu."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Covid cases in India: Coronavirus cases cross 4,500; Kerala tops chart
India has reported a total of 4,866 active Covid-19 cases as of June 5, 2025, according to the Ministry of Health and Family Welfare. Kerala leads the chart with 1,487 cases, followed by Delhi (562), and West Bengal (538). Tired of too many ads? go ad free now The complete state-wise count includes Rajasthan (103), Maharashtra (526), and Gujarat (508), Karnataka (436), Tamil Nadu (213), Uttar Pradesh (198), Haryana (63), Bihar (31), Madhya Pradesh (30), Odisha (18), Punjab (16), Andhra Pradesh (50), Telangana (3), Jharkhand (8), Assam (8), Goa (8), Chhattisgarh (19), Uttarakhand (6), Sikkim (9), Jammu & Kashmir (5), Chandigarh (2), Puducherry (17), Himachal Pradesh (1). Seven regions — Tripura, Arunachal Pradesh, Manipur, Mizoram, Meghalaya, Nagaland, and Andaman & Nicobar Islands — have reported zero active cases. . Covid fatalities, however, underline a clear trend — people with pre-existing health problems remain highly vulnerable. In Delhi, a five-month-old infant with multiple health issues and an 87-year-old man with several chronic conditions died. Karnataka reported the deaths of a cancer patient and another with severe abdominal complications. Maharashtra recorded three deaths, including elderly patients with heart disease, cancer, diabetes, and organ failure. Globally, China, Singapore, Taiwan, and United States have reported the highest number of cases.
India.com
an hour ago
- India.com
COVID 19 Cases in India: Active Cases Rise To 4866, Delhi With 562 Cases- Kerala Leading The Chart With 1487 Cases
COVID-19 Cases Rising In India Highlights: India is once again witnessing an unsettling rise in COVID-19 cases, with the number of active infections climbing to 4866, according to the Ministry of Health and Family Welfare's latest update as of 8:00 AM IST, June 5, 2025. Leading the current spike is Kerala pushing its active caseload to 1487, nearly half of the country's total. Meanwhile, West Bengal added 106 new cases, increasing its active tally to 538, while the national capital Delhi recorded 105 new infections, taking its active cases to 562. As per May 2025 classifications by the World Health Organization (WHO), subvariants LF.7 and NB.1.8.1 are categorized as Variants Under Monitoring, meaning they are not yet deemed as Variants of Concern or Variants of Interest. However, these strains are suspected to be contributing to the rising infections not just in India but also across China and other parts of Asia. Despite the emergence of new subvariants, the JN.1 strain remains the most dominant, accounting for a staggering 53% of all positive cases across the country. According to data from the Indian SARS-CoV-2 Genomics Consortium (INSACOG), a case of NB.1.8.1 was detected in Tamil Nadu in April, while four cases of LF.7 were identified in Gujarat earlier this month. With the virus subtly shifting form and symptoms evolving, health authorities are urging the public to maintain precautionary measures, including hygiene, mask use in crowded places, and timely testing. Although hospitalisation remains low, experts warn that complacency could reverse progress. Stay informed, and if you're experiencing mild symptoms like fatigue, a sore throat, or gastrointestinal discomfort, it's best to test early and isolate to prevent further spread.
Time of India
an hour ago
- Time of India
A common drug shows promise for patients with liver disease
A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in treating severe liver conditions like MASH and liver fibrosis. The study, involving 154 participants, demonstrated significant improvements in MASH and fibrosis among those receiving dapagliflozin compared to the placebo group, suggesting a potential new treatment avenue. Liver disease accounts for two million deaths annually. This is 4% of all deaths (1 out of every 25 deaths worldwide), as per the data from 2023. Liver disease is a growing global health concern. A new study suggests that a widely used diabetes medication may offer hope for patients suffering from progressive liver disease. A recent clinical trial conducted in China and published in The BMJ suggests that the type 2 diabetes drug dapagliflozin can help patients with severe liver conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, which have limited treatment options. What does the diabetes drug do (Pic courtesy: iStock) Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, which is widely used to treat type 2 diabetes, has been shown to improve progressive liver disease. The Chinese researchers found that the drug improved metabolic dysfunction-associated steatohepatitis (MASH), a condition where excess fat accumulates in the liver, leading to inflammation and liver fibrosis (a buildup of scar tissue). MASH affects more than 5% of adults, and it is also common (30%) in people with diabetes or obesity. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Switch to UnionBank Rewards Card UnionBank Credit Card Apply Now Undo This can progress to cirrhosis in up to 25% of individuals. Though previous studies have suggested that SGLT-2 inhibitors can improve liver fat content, liver enzymes, and liver stiffness, no trial has been carried out in patients with MASH. The study To understand the effects of dapagliflozin in patients with MASH, the researchers conducted a study. The 48-week study had 154 participants, who were diagnosed with MASH following liver biopsies at six Chinese medical centers from November 2018 to March 2023. Participants had an average age of 35, and 85% were men. Nearly half (45%0 had type 2 diabetes, and most had evidence of liver fibrosis at various stages (33% stage 1, 45% stage 2, 19% stage 3). Following an initial screening biopsy, the participants were randomly assigned to receive 10 mg of dapagliflozin or a matching placebo once daily for 48 weeks. They attended health education sessions twice a year. The researchers also recorded body weight, blood pressure, blood glucose, liver enzymes, physical activity, diet, insulin, and lipids of the participants throughout the trial. MASH improvement was defined as a decrease of at least 2 points in non-alcoholic fatty liver disease activity score (NAS) or a NAS of 3 points or less. By the end of the study, which is after 48 weeks, the researchers observed that 53% (41 of 78) participants in the dapagliflozin group showed improvement in MASH without worsening of fibrosis (defined as no increase in fibrosis stage) compared with 30% (23 of 76) in the placebo group. 23% (18 of 78) participants in the dapagliflozin group showed resolution of MASH without worsening of fibrosis, compared with 8% (6 of 76) in the placebo group. Trump Health Scare: 'Cognitive Decline' Spotted? Political Adviser's BIG Warning Amid Dementia Claim They also saw improvement in fibrosis without worsening of MASH in 45% (35 of 78) participants in the dapagliflozin group compared with 20% (15 of 76) in the placebo group. 1% (1 of 78) in the dapagliflozin group and 3% (2 of 76) in the placebo group discontinued the treatment because of adverse events. What are the experts saying Fatty liver 'Our findings indicate that dapagliflozin may affect key aspects of MASH by improving both steatohepatitis and fibrosis,' they said. They added that large-scale and long-term trials are needed to further confirm these effects. The trial was conducted in a Chinese population, which limits its broader generalisability. They also noted that with the emergence of more drugs, therapeutic decisions will likely become increasingly tailored to individual patient profiles, they write. 'Ideally, such treatments should provide cardiovascular benefit, have an established safety profile, and be accessible to broad and diverse patient populations,' they concluded. One step to a healthier you—join Times Health+ Yoga and feel the change
